Fludarabine phosphate
Fludara, Oforta (fludarabine phosphate) is a small molecule pharmaceutical. Fludarabine phosphate was first approved as Fludara on 1991-04-18. It is used to treat b-cell chronic lymphocytic leukemia and non-hodgkin lymphoma in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Fludarabine phosphate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
FLUDARABINE PHOSPHATE | Sandoz | N-022137 RX | 2007-09-21 | 1 products, RLD, RS |
Show 2 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
fludarabine phosphate | ANDA | 2021-07-22 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
Clinical
Clinical Trials
36 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | 3 | 6 | 8 | 6 | 22 |
Ventricular premature complexes | D018879 | I49.3 | — | 1 | — | 2 | 1 | 4 | |
Ventricular tachycardia | D017180 | I47.2 | — | 1 | 1 | 2 | — | 4 | |
Brugada syndrome | D053840 | Orphanet_130 | I49.8 | — | — | — | 1 | 1 | 2 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Supraventricular tachycardia | D013617 | HP_0004755 | I47.1 | — | — | 1 | — | 2 | 3 |
Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 1 | 2 | — | — | 3 |
Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | 2 | — | — | 3 |
Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | 1 | 1 | — | 1 | 3 |
Heart arrest | D006323 | EFO_0009492 | I46 | — | — | 2 | — | — | 2 |
Recurrence | D012008 | — | 1 | 1 | — | — | 1 | ||
Atrial flutter | D001282 | EFO_0003911 | — | — | 1 | — | — | 1 | |
Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | 1 | — | — | 1 |
Coronary disease | D003327 | — | — | 1 | — | — | 1 | ||
Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | 1 | — | — | 1 |
Show 5 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Arrhythmogenic right ventricular dysplasia | D019571 | Orphanet_247 | I42.8 | — | 1 | — | — | 1 | 2 |
Blood pressure | D001794 | EFO_0004325 | — | 1 | — | — | — | 1 | |
Pain | D010146 | EFO_0003843 | R52 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | FLUDARABINE PHOSPHATE |
INN | fludarabine |
Description | Fludarabine phosphate is a purine arabinonucleoside monophosphate having 2-fluoroadenine as the nucleobase. A prodrug, it is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. Once incorporated into DNA, 2-fluoro-ara-ATP functions as a DNA chain terminator. It is used for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to, or whose disease has progressed during, treatment with at least one standard alkylating-agent containing regimenas. It has a role as an antimetabolite, an antineoplastic agent, an immunosuppressive agent, an antiviral agent, a prodrug and a DNA synthesis inhibitor. It is an organofluorine compound, a nucleoside analogue and a purine arabinonucleoside monophosphate. It is functionally related to a 2-fluoroadenine. |
Classification | Small molecule |
Drug class | antineoplastics (arabinofuranosyl derivatives) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O |
Identifiers
PDB | — |
CAS-ID | 75607-67-9 |
RxCUI | 25102 |
ChEMBL ID | CHEMBL1096882 |
ChEBI ID | 63599 |
PubChem CID | 30751 |
DrugBank | DB01073 |
UNII ID | P2K93U8740 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 181 documents
View more details
Safety
Black-box Warning
Black-box warning for: Fludarabine phosphate
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,027 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more